Drug intelligence / Profile preview

ECI-103

Development stage: Preclinical
Lead developer: ECI Therapeutics

Overview

ECI-103 is an investigational drug being developed for the treatment of wounds and injuries. It is currently in preclinical development, and detailed information about its mechanism of action, molecular structure, or modality has not been publicly disclosed. The drug is part of the pipeline at Eci Therapeutics, a company focused on developing novel therapies for various indications including xerophthalmia and limbal stem cell deficiency[1].

Beyond the preview

Go deeper on ECI-103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ECI-103.

Explore the full profile